Novartis and Ratio Enter Radiotherapeutics Partnership Worth $745m
Novartis and Ratio Therapeutics have entered into a worldwide licence and collaboration agreement worth $745m to advance a somatostatin receptor 2 (SSTR2)-targeting ...
Insights into the latest developments in CDMO services and manufacturing.
Continue readingExpert perspectives on the evolving needs of injectable therapies and packaging.
Continue readingExploring the latest developments in inhalation technologies, respiratory delivery and sustainability
Continue readingAdvertisement
Advertisement
Advertisement
Advertisement
Advertisement